338 related articles for article (PubMed ID: 16494641)
1. Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes.
Dettmar PW; Sykes J; Little SL; Bryan J
Int J Clin Pract; 2006 Mar; 60(3):275-83. PubMed ID: 16494641
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial.
Janiak P; Thumshirn M; Menne D; Fox M; Halim S; Fried M; Brühlmann P; Distler O; Schwizer W
Aliment Pharmacol Ther; 2007 Nov; 26(9):1259-65. PubMed ID: 17944740
[TBL] [Abstract][Full Text] [Related]
3. Ranitidine, cimetidine, antacids, and gastro-oesophageal reflux: results of a 20-hour oesophageal pH study.
Desechalliers JP; Galmiche JP; Touchais JY; Denis P; Colin R
Int J Clin Pharmacol Res; 1984; 4(3):217-22. PubMed ID: 6092288
[TBL] [Abstract][Full Text] [Related]
4. The suppression of gastro-oesophageal reflux by alginates.
Dettmar PW; Hampson FC; Taubel J; Lorch U; Johnstone LM; Sykes J; Berry PJ
Int J Clin Pract; 2007 Oct; 61(10):1654-62. PubMed ID: 17681004
[TBL] [Abstract][Full Text] [Related]
5. Effect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate-severe esophagitis.
Fiorucci S; Santucci L; Morelli A
Am J Gastroenterol; 1990 Nov; 85(11):1458-62. PubMed ID: 2239873
[TBL] [Abstract][Full Text] [Related]
6. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group.
Wiklund I; Bardhan KD; Müller-Lissner S; Bigard MA; Bianchi Porro G; Ponce J; Hosie J; Scott M; Weir D; Fulton C; Gillon K; Peacock R
Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):19-27. PubMed ID: 9615259
[TBL] [Abstract][Full Text] [Related]
7. Clinical and laboratory studies of the antacid and raft-forming properties of Rennie alginate suspension.
Tytgat GN; Simoneau G
Aliment Pharmacol Ther; 2006 Mar; 23(6):759-65. PubMed ID: 16556178
[TBL] [Abstract][Full Text] [Related]
8. Empiric therapy for gastroesophageal reflux disease.
Schindlbeck NE; Klauser AG; Voderholzer WA; Müller-Lissner SA
Arch Intern Med; 1995 Sep; 155(16):1808-12. PubMed ID: 7654116
[TBL] [Abstract][Full Text] [Related]
9. Oral ranitidine and duration of gastric pH >4.0 in infants with persisting reflux symptoms.
Salvatore S; Hauser B; Salvatoni A; Vandenplas Y
Acta Paediatr; 2006 Feb; 95(2):176-81. PubMed ID: 16449023
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants.
Corvaglia L; Aceti A; Mariani E; De Giorgi M; Capretti MG; Faldella G
Aliment Pharmacol Ther; 2011 Feb; 33(4):466-70. PubMed ID: 21158879
[TBL] [Abstract][Full Text] [Related]
11. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux.
Omari TI; Haslam RR; Lundborg P; Davidson GP
J Pediatr Gastroenterol Nutr; 2007 Jan; 44(1):41-4. PubMed ID: 17204951
[TBL] [Abstract][Full Text] [Related]
12. Onset of action of antisecretory drugs: beneficial effects of a rapid increase in intragastric pH in acid reflux disease.
Pipkin GA; Mills JG
Scand J Gastroenterol Suppl; 1999; 230():3-8. PubMed ID: 10499455
[TBL] [Abstract][Full Text] [Related]
13. Treatment of reflux disease during pregnancy and lactation.
Dağlı Ü; Kalkan İH
Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S53-S56. PubMed ID: 29199169
[TBL] [Abstract][Full Text] [Related]
14. [Drug therapy of gastroesophageal reflux (a prospective controlled clinical trial)].
Wittmann T; Rosztóczy A; Fehér A; Jármay K; Oláh T; Szendrényi V; Kiss I
Orv Hetil; 1998 May; 139(18):1077-81. PubMed ID: 9608770
[TBL] [Abstract][Full Text] [Related]
15. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.
Sweis R; Kaufman E; Anggiansah A; Wong T; Dettmar P; Fried M; Schwizer W; Avvari RK; Pal A; Fox M
Aliment Pharmacol Ther; 2013 Jun; 37(11):1093-102. PubMed ID: 23600790
[TBL] [Abstract][Full Text] [Related]
16. Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease.
Størdal K; Johannesdottir GB; Bentsen BS; Knudsen PK; Carlsen KC; Closs O; Handeland M; Holm HK; Sandvik L
Arch Dis Child; 2005 Sep; 90(9):956-60. PubMed ID: 16113133
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial.
Manabe N; Haruma K; Ito M; Takahashi N; Takasugi H; Wada Y; Nakata H; Katoh T; Miyamoto M; Tanaka S
Dis Esophagus; 2012 Jul; 25(5):373-80. PubMed ID: 22050449
[TBL] [Abstract][Full Text] [Related]
18. Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH.
Del Buono R; Wenzl TG; Ball G; Keady S; Thomson M
Arch Dis Child; 2005 May; 90(5):460-3. PubMed ID: 15851425
[TBL] [Abstract][Full Text] [Related]
19. Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole.
Dettmar PW; Hampson FC; Jain A; Choubey S; Little SL; Baxter T
Indian J Med Res; 2006 Apr; 123(4):517-24. PubMed ID: 16783042
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and cost issues in managing patients with gastroesophageal reflux disease.
Garnett WR
Am J Hosp Pharm; 1993 Apr; 50(4 Suppl 1):S11-8. PubMed ID: 8097363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
